Minnesota-based leading medical device manufacturer
) Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT
and Viva Quad S cardiac resynchronization therapy defibrillators
(CRT-D) have recently received the U.S. Food and Drug
Administration (FDA) approval.
With these sanctions, the new system will now enable surgeons to
provide optimal and more efficient Cardiac Resynchronization
Therapy (CRT) to heart-failure patients.
Following the news release, Medtronic's share prices rose 1.4%
to eventually close at $62.15 on Friday.
An individual whose heart does not beat sufficiently on its own
needs a CRT heart device that sends small, undetectable electrical
impulses to the lower chambers of the heart to help them beat
together in a more synchronized manner.
Attain Quadripolar Lead
Quadripolar leads are insulated wires with four electrodes that
connect a heart device and a patient's heart. These wires are used
to transmit information signals from one's heart to the device and
deliver electrical impulses back to the heart, making it beat
Medtronic's Attain Performa Model 4298 left-heart quadripolar
lead offers supplementary options to physicians to treat different
patient anatomies. Its unique feature includes 16-pacing
configurations and shorter spacing between the two center
electrodes. The Model 4298 lead has a canted shape and steroid on
all four electrodes for lower pacing thresholds. This Attain
Performa portfolio has already received the CE Mark in Europe in
Compared to traditional leads, the additional pacing
configurations offered by this system helps surgeons optimize CRT
delivery while the narrow-spaced bipole helps avoid phrenic nerve
capture. This system can thus offer better patient care by reducing
the incidence of phrenic nerve stimulation that can result in
partial or complete respiratory insufficiency as a side effect in
What is Viva CRT-D?
Medtronic's Viva Quad XT and Viva Quad S are two CRT-D devices
that utilize two different algorithms. While the Viva XT CRT-D
device incorporates the company's AdaptiveCRT algorithm, the Viva S
device features the Ensure CRT Suite.
The company's proprietary Adaptive CRT algorithm delivers
physiologic pacing by preserving a patient's normal heart rhythms
and automatically adjusts to patients' needs to customize therapy.
This system also includes the VectorExpress technology, which
reduces lead programming time to two minutes. This technology
provides helpful clinical information to physicians to choose
optimal pacing configurations for each patient.
On the other hand, the Ensure CRT Suite consists of five
integrated algorithms that automatically work in tandem to ensure
efficient CRT delivery during challenging conditions. This system
features three algorithms that can maximize CRT response even in
the presence of atrial fibrillation.
Both these CRT-D devices boast increased device longevity and
promise to escalate patient comfort. Medtronic expects to make the
quadripolar leads and the two CRT-D devices available to physicians
Medtronic is dedicated to advancing patient care for heart
failure individuals ever since its first commercialized cardiac
resynchronization therapy came into being in the U.S. Management
expects the FDA nod for the new Attain Performa lead and the two
Viva Quad devices will add yet another feather to its cap.
Currently, Medtronic carries a Zacks Rank #2 (Buy). Other
well-ranked stocks in the Medical Products industry include OraSure
Technologies, Inc. (
), Abaxis, Inc. (
) and AtriCure, Inc. (
). While OraSure sports a Zacks Rank #1 (Strong Buy), Abaxis and
AtriCure hold a Zacks Rank #2 (Buy) each.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
ORASURE TECH (OSUR): Free Stock Analysis Report
ATRICURE INC (ATRC): Free Stock Analysis Report
To read this article on Zacks.com click here.